Dr. Dolly Jacob: Solubility & Bioavailability
Dr. Dolly Jacob, Director of Integrated Development Services at Quotient Sciences featured in Drug Development & Delivery looking at the challenges of solubility & bioavailability.
Quotient Sciences Expands Formulation Development Capabilities at Nottingham, UK
An expansion of our early-phase formulation development capabilities for oral dosage forms at our Nottingham, UK, facility builds upon our existing formulation capabilities.
Andy Lewis speaks about modified-release dosage forms in Drug Development & Delivery
Andy Lewis, Vice President, Pharmaceutical Sciences, has written an article for Drug Development & Delivery entitled, "Alternative Strategies for Development of Modified-Release Dosage Forms"
Quotient Sciences SME comments on solubility & bioavailability challenges in Drug Development & Delivery feature article
John McDermott, Quotient Sciences' Executive Drug Development Consultant, discusses Integrated Development Strategies Overcome Solubility Challenges, in Drug Development & Delivery's Special Feature.
Oxilio OXL001 formulation optimisation and clinical trial preparation contract with Quotient Sciences
Oxilio signed an exclusive global licensing agreement with TRx Biosciences on 20th October 2021 for the use of their platformtechnology to support the development of Oxilio’s formulation, OXL001. Oxilio has since progressed the product and nowsigned a significant service contract with Quotient Sciences, a drug development and manufacturing accelerator, to support the formulation development and preparation of clinical trials for OXL001.